ASP Isotopes Inc. (ASPI) as of December 31, 2025 presents a deeply negative liquidation posture for equity holders. Total assets of $498.0M against total liabilities of $235.1M yields a book equity of approximately $263M, but under liquidation haircuts the picture deteriorates substantially. The dominant asset is cash and cash equivalents of $285.6M (including $267.4M in cash equivalents), which recovers at 100% and is the primary support for any equity recovery. Held-to-maturity short-term investments of $47.7M also recover near par. However, the $32.0M current notes receivable (the Renergen loan, described in the prior filing) carries collection risk given Renergen's financial distress and the repayment extension history; a practitioner would apply a significant haircut here. The $45.9M in other long-term investments (likely the Renergen equity position and the IsoBio preferred stock investment per MD&A) would receive a 0% or near-0% haircut given illiquidity and speculative nature. The $27.9M deployed into equity securities (also consistent with the Renergen and IsoBio positions) similarly recovers poorly in distress. PP&E of $33.5M at net book value applies a 50-70% recovery, yielding $17-23M. Goodwill of $8.6M and intangibles of $1.5M receive 0% recovery. The $199.3M convertible notes payable (long-term) is held at face value in liquidation and represents the single largest liability, absorbing the majority of recovered asset value after current liabilities are settled. Current liabilities of $32.7M include $12.9M of current long-term debt, $5.8M accounts payable, $6.2M accrued liabilities, and $3.6M accrued salaries. Noncontrolling interest of $58.7M must also be deducted from any residual before equity holders receive recovery. The $231.3M accumulated deficit reflects cumulative losses driven by large non-cash fair value changes on the convertible notes (the prior 10-Q disclosed $64.5M of convertible note fair value change in operating activities for just nine months), heavy G&A of $48.2M, and $12.4M R&D in the annual period. The 10-K/A filing provided here covers only the proxy-related items (Items 10-14) amended after the original 10-K filing; the balance sheet data comes from TAG_CONTEXT. Prior period comparison is to the 10-Q for September 30, 2025, which showed $113.9M in cash — the year-end $285.6M reflects the large equity raise ($320M gross proceeds per the cash flow statement). That capital raise dramatically improved the cash recovery floor but also funded speculative investments that carry poor liquidation recovery. The convertible notes at $199.3M long-term remain the dominant liability overhang. Net equity recovery to common shareholders under liquidation is positive but narrow given the NCI claim and face-value liability treatment of the converts.
▼ Community Notes